Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases
Authors' conclusion
We found that the BNT162b2 mRNA vaccine was similarly effective against COVID-19 infection in adolescents with and without IRD.
Study context
- Population
- Adolescents aged 12–18 years, Clalit Health Services, Israel, February to December 2021
- Participants
- 1,639 vs 524,471
- Exposure
- Adolescents with juvenile-onset IRD vs adolescents without immune rheumatic disease
- IRDn = 1,639
- Controlsn = 524,471reference
- Outcome
- Documented COVID-19 infection in relation to vaccination status and immunomodulatory therapy; vaccine effectiveness as one minus the risk ratio
Methodological detailsobservational
- Observational
Main finding
As reported in the abstract
COVID-19 infection rate after the second vaccine dose
P = 0.99
Observational data: associations, not effects.
Further findings
- Estimated vaccine effectiveness in adolescents with IRD
- 76.3% · after first dose · after second dose 94.8% · after third dose 99.2%
Original publication
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases. Rheumatology (Oxford). Published 3 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →